Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample

in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

02/06/2026

𝟏 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦. 𝟗𝟓+ 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬. 𝐂𝐨𝐮𝐧𝐭𝐥𝐞𝐬𝐬 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐝.
The Idylla™ Platform empowers pathologists and oncologists worldwide with fast, reliable molecular biomarker testing. Every day, it helps them make confident, data-driven decisions.

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 👉 https://www.biocartis.com/en/meet-idylla/idylla-platform?utm_source=facebook&utm_medium=social&utm_campaign=idylla-platform

Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries

01/06/2026

𝗛𝗮𝘃𝗶𝗻𝗴 𝗮 𝗯𝗹𝗮𝘀𝘁 𝗮𝘁 𝗔𝗦𝗖𝗢!
📍Booth 18152 | 🗺️ Chicago, IL, US

Join us at booth 𝟭𝟴𝟭𝟱𝟮 to discover how the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 can deliver molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀⏱️ Because securing targeted answers shouldn't require waiting on NGS....
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 👉 https://www.biocartis.com/en-US/meet-idylla

28/05/2026

🚀 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗶𝘀 𝗻𝗼𝘄 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿𝗲𝗱 𝗶𝗻 𝗨𝗸𝗿𝗮𝗶𝗻𝗲
We are proud to share that the Idylla™ Platform is now successfully registered in Ukraine. In a healthcare environment facing severe disruption, 𝗳𝗮𝘀𝘁 𝗮𝗻𝗱 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗰𝗮𝗻 𝗺𝗮𝗸𝗲 𝗮 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 for patients and HCPs navigating a cancer diagnosis — enabling faster patient management decisions when time matters most⏱️

At Biocartis, we remain committed to expanding access to accurate molecular diagnostics worldwide 🎗️

🤝 𝗠𝗲𝗲𝘁 𝗼𝘂𝗿 𝗨𝗸𝗿𝗮𝗶𝗻𝗶𝗮𝗻 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗼𝗿 BIONIX LAB:
https://lnkd.in/ePjT4ufS

👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺: https://lnkd.in/g_7rKdP

27/05/2026

𝐒𝐩𝐫𝐢𝐧𝐠 𝐭𝐢𝐦𝐞! 𝐓𝐢𝐦𝐞 𝐭𝐨 𝐠𝐞𝐭 𝐭𝐡𝐞 𝐬𝐮𝐧𝐬𝐜𝐫𝐞𝐞𝐧 𝐨𝐮𝐭☀️
May is Melanoma & Skin Cancer Awareness Month, a month in which we take time to raise awareness on preventing and treating skin cancer and melanoma 🖤

Biocartis offers the 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐁𝐑𝐀𝐅 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐓𝐞𝐬𝐭* for patients with advanced melanoma. This Test offers 𝐟𝐮𝐥𝐥𝐲 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝟕 𝐁𝐑𝐀𝐅 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐬 in codon 600 directly from 𝟏 𝐅𝐅𝐏𝐄 𝐭𝐢𝐬𝐬𝐮𝐞 𝐬𝐞𝐜𝐭𝐢𝐨𝐧 👉 https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-braf-mutation-test?utm_source=facebook&utm_medium=social&utm_campaign=idylla-braf-mutation-test

*CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC. For Research Use Only (RUO), not for use in diagnostic procedures, in the US.
The Skin Cancer Foundation

25/05/2026

Revolutionize your CRC diagnostics with Idylla™ 🏆

⏱️Speed up your therapy decisions and alleviate patient anxiety*!

Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, with results in only three hours. Ensure they receive the most effective treatment without delay.

👉 Read morehttps://www.biocartis.com/sites/default/files/2026-03/CRC%20Oncologist%20-%20Leaflet%20-%20Mar2026.pdf

Your patients, our priority. Guiding them to the right therapy within hours ⚡

*Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.
The content of this post is only applicable to Idylla™ KRAS & NRAS-BRAF Mutation Tests and Idylla™ MSI & CDx MSI Tests which are CE-marked in Europe; Idylla™ MSI Test which is cleared in the US under K211181 for Lynch Syndrome; and Idylla™ CDx MSI Test which is approved in the US under P250005. Idylla™ KRAS & NRAS-BRAF Mutation Assays are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.

22/05/2026

𝗪𝗲'𝗿𝗲 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗔𝗦𝗖𝗢! 🚀
📅 29 May - 2 June |📍Booth 18152 | 🗺️ Chicago, IL, US

Join us at booth 𝟭𝟴𝟭𝟱𝟮 to discover how the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 can deliver molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀⏱️Because securing targeted answers shouldn't require waiting on NGS....

𝗟𝗲𝘁'𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝗮𝘁 𝗔𝗦𝗖𝗢 👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://lnkd.in/eSx8X2ZV

20/05/2026

💡 𝐋𝐞𝐭 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐭𝐡𝐞 𝐰𝐚𝐲 𝐲𝐨𝐮 𝐰𝐨𝐫𝐤
The Idylla™ Platform is a revolutionary, fully automated, real-time PCR-based molecular testing system designed to offer 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐨𝐧𝐥𝐲 𝟑 𝐡𝐨𝐮𝐫𝐬. Accessible on demand and no need for batching. It makes molecular testing 𝐞𝐚𝐬𝐲, 𝐟𝐚𝐬𝐭 𝐚𝐧𝐝 𝐬𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐟𝐨𝐫 𝐚𝐧𝐲 𝐥𝐚𝐛.

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 👉 https://www.biocartis.com/en/meet-idylla/idylla-platform?utm_source=facebook&utm_medium=social&utm_campaign=idylla-platform

Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries.

18/05/2026

𝐈𝐝𝐲𝐥𝐥𝐚™. 𝐁𝐚𝐜𝐤𝐞𝐝 𝐛𝐲 𝟑𝟎𝟎+ 𝐩𝐞𝐞𝐫-𝐫𝐞𝐯𝐢𝐞𝐰𝐞𝐝 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬
The Idylla™ Platform isn’t just fast, it's highly accurate and scientifically proven. With over 300 peer-reviewed publications, Idylla™ demonstrates real-world impact in molecular biomarker testing.

𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 👉 https://www.biocartis.com/en/meet-idylla/publications?utm_source=facebook&utm_medium=social&utm_campaign=publications

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.